Evidence map›Paper›PMID 42287760›Full record

ArticleJACC. Basic to translational science2026

Targeting Inflammation by Pioglitazone and its R-Enantiomer Mitigates Pathological Myocardial Remodeling in Murine Hypertrophic Cardiomyopathy.

Anna-Theresa Pfaller, Claudia Veneziano, Sarala Raj Murthi, Jan B Stöckl, Bachuki Shashikadze, Florian Flenkenthaler, Josh Gorham, Alessandra Moretti, Ana Kitanovic, Linden J Gearing and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Basic to translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The Metabolic-Inflammatory Axis in Hypertrophic Cardiomyopathy.JACC. Basic to translational science · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Anna-Theresa PfallerDepartment of Congenital Heart Defects and Pediatric Cardiology, German Heart Centre Munich, Technical University of Munich, School of Medicine and Health, Munich, Germany; DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany.
Claudia VenezianoDepartment of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, Catanzaro, Italy.
Sarala Raj MurthiDepartment of Congenital Heart Defects and Pediatric Cardiology, German Heart Centre Munich, Technical University of Munich, School of Medicine and Health, Munich, Germany.
Jan B StöcklLaboratory for Functional Genome Analysis LAFUGA, Gene Center, LMU Munich, Munich, Germany.
Bachuki ShashikadzeLaboratory for Functional Genome Analysis LAFUGA, Gene Center, LMU Munich, Munich, Germany.
Florian FlenkenthalerLaboratory for Functional Genome Analysis LAFUGA, Gene Center, LMU Munich, Munich, Germany.
Josh GorhamDepartment of Genetics, Harvard Medical School, Boston, Massachusetts, USA.
Alessandra MorettiDZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany; First Department of Medicine and Regenerative Medicine in Cardiovascular Diseases, Klinikum Rechts der Isar, School of Medicine and Health, Technical University of Munich, Germany.
Ana KitanovicGerman Rheumatism Research Centre, Berlin, Germany.
Linden J GearingGerman Rheumatism Research Centre, Berlin, Germany.
Frederik HeinrichGerman Rheumatism Research Centre, Berlin, Germany; Zuse Institute Berlin, Berlin, Germany.
Pawel DurekGerman Rheumatism Research Centre, Berlin, Germany; Zuse Institute Berlin, Berlin, Germany.
Katrin LehmannGerman Rheumatism Research Centre, Berlin, Germany.
Mir-Farzin MashreghiGerman Rheumatism Research Centre, Berlin, Germany.
Peter EwertDepartment of Congenital Heart Defects and Pediatric Cardiology, German Heart Centre Munich, Technical University of Munich, School of Medicine and Health, Munich, Germany; DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany.
Thomas FröhlichLaboratory for Functional Genome Analysis LAFUGA, Gene Center, LMU Munich, Munich, Germany.
Joachim P SchmittInstitute of Pharmacology, University Hospital Düsseldorf and Cardiovascular Research Institute Düsseldorf (CARID), Heinrich-Heine-University, Düsseldorf, Germany.
Nadine SpielmannInstitute of Experimental Genetics and German Mouse Clinic, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany.
Martin Hrabě de AngelisInstitute of Experimental Genetics and German Mouse Clinic, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany.
Manuel SchmidDepartment of Genetics, Harvard Medical School, Boston, Massachusetts, USA; Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.
Christopher N ToepferDepartment of Genetics, Harvard Medical School, Boston, Massachusetts, USA; Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.
Eicke LatzGerman Rheumatism Research Centre, Berlin, Germany.
Karin KlingelCardiopathology, Institute for Pathology and Neuropathology, University Hospital of Tübingen, Tübingen, Germany.
Gianluca SantamariaDepartment of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, Catanzaro, Italy; First Department of Medicine and Regenerative Medicine in Cardiovascular Diseases, Klinikum Rechts der Isar, School of Medicine and Health, Technical University of Munich, Germany; Interdepartmental Center of Services (CIS), Omics Sciences and Biobank, "Magna Graecia" University, Catanzaro, Italy.
Jonathan G SeidmanDepartment of Genetics, Harvard Medical School, Boston, Massachusetts, USA.
Christine E SeidmanDepartment of Genetics, Harvard Medical School, Boston, Massachusetts, USA.
Cordula M WolfDepartment of Congenital Heart Defects and Pediatric Cardiology, German Heart Centre Munich, Technical University of Munich, School of Medicine and Health, Munich, Germany; DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany. Electronic address: wolf@dhm.mhn.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertrophic cardiomyopathy (HCM) is driven by sarcomeric mutations that cause energetic failure and secondary inflammation. This study demonstrates that targeting this metabolic-inflammatory axis with pioglitazone or its peroxisome proliferator-activated receptor gamma inactive enantiomer, R-pioglitazone, reverses disease progression in a murine HCM model. Both agents restored mitochondrial function (including Mitochondrial Pyruvate Carrier 1 [MPC1] levels) and resolved inflammation. Notably, R-pioglitazone showed superior efficacy, reducing interstitial fibrosis by >95% and hypertrophy by 33% without affecting healthy control hearts. These findings identify R-pioglitazone as a promising, mechanism-based candidate for disease-modifying therapy in HCM.

Indexed as

hypertrophic cardiomyopathyinflammation and oxidative stressmitochondrial dysfunctionmyocardial hypertrophy and fibrosispioglitazone

Identifiers

PMID42287760
PMCPMC13279018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.